Company Overview
About Bluejay Therapeutics
Bluejay Therapeutics is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Redwood City, California. The company is focused on developing innovative therapies for chronic liver diseases, with hepatitis B virus (HBV) infection as its primary indication. Chronic HBV is a significant unmet medical need affecting an estimated 296 million people worldwide; while existing antivirals like tenofovir and entecavir suppress the virus effectively, they do not achieve a functional cure and require lifelong treatment. Bluejay''s therapeutic programs aim to achieve functional cure — defined as durable suppression of HBV surface antigen (HBsAg) after treatment ends — by targeting viral replication mechanisms and immune restoration simultaneously.
Business Model & Competitive Advantage
The company''s lead candidate, BJT-778, is a small molecule capsid assembly modulator (CAM) that interferes with HBV replication at the viral capsid formation stage, representing a mechanism distinct from approved nucleoside analogs. Bluejay has also explored combination approaches that pair its antiviral candidates with immune-modulatory agents to address both the viral and immunological dimensions of chronic HBV. The company raised over $100M in total funding from investors including Lilly Asia Ventures, Forbion, and others — reflecting global investor interest in a disease particularly prevalent in Asia-Pacific, sub-Saharan Africa, and other emerging markets.
Competitive Landscape 2025–2026
Bluejay operates in a competitive but high-value segment of hepatitis B drug development, alongside companies including Assembly Biosciences, Arrowhead Pharmaceuticals, Vir Biotechnology, and Gilead Sciences. The functional cure aspiration — ending the need for lifelong antiviral therapy — represents a multi-billion dollar commercial opportunity if achieved, as it would serve the tens of millions of patients currently on suppressive therapy who seek a finite treatment course. Bluejay''s clinical progress and investor backing position it as a credible participant in the race to deliver the first broadly applicable functional cure for chronic HBV.
Frequently Asked Questions
Similar Brands
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Compare Bluejay Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Bluejay Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Bluejay Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Bluejay Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →